- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02127892
SCID Bu/Flu/ATG Study With T Cell Depletion
Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The study is being conducted to assess the following:
- overall survival
- event-free survival (events are defined as: death,non-engraftment/2nd transplant, immune reconstitution failure)
- acute toxicity of the conditioning regimen
- engraftment frequency immune reconstitution frequency and tempo acute and chronic graft-versus-host disease (GVHD), frequency and severity.
The outcome from this protocol will be compared to the retrospective cohort consisting of all patients who have undergone haplo-identical HSCT for SCID at CHLA from 1984-2006 based on the assessment of the above-listed endpoints.
The CliniMACS device will be used for CD34+ selection in place of the Isolex 300i. The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Children's Hospital Los Angeles
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- All patients with SCID who lack a histocompatible sibling or HLA-matched related donor will be considered as candidates for this study protocol.
Eligible patients must have adequate physical function to tolerate the chemotherapy conditioning regimen and the HSCT, as measure by:
- Renal: creatinine clearance or GFR ≥50 ml/min/1.73m2, and not requiring dialysis
- Pulmonary: Because patients with SCID frequently present with infectious pneumonia causing ventilatory failure, patients will be considered for enrollment in the study even if respiratory failure requiring mechanical ventilatory support is present. In patients recently diagnosed with pneumonia, efforts to stabilize the respiratory status will be made prior to enrollment in the study.
- Infectious disease status. The presence of infection per se will not be a reason for exclusion from the study. Patients with SCID are frequently infected with both routine pathogens as well as opportunistic infections. Antibiotic, antifungal and antiviral prophylaxis and therapy will be instituted as clinically indicated. Despite the use of antimicrobial therapy, the ability to control infections will not be achieved unless HSCT is performed. Therefore, subjects may be enrolled in the study, even though infection is present, because control of infection may depend on engraftment of a donor immune system.
- Patients will be 0-21 years of age.
Exclusion Criteria:
- Patient with histocompatible sibling or other related donor
- End-organ failure that precludes the ability to tolerate the transplant procedure, including conditioning.
- Renal failure requiring dialysis
- Congenital heart disease resulting in congestive heart failure
- Severe CNS disease, e.g., coma or intractable seizures
- Ventilatory failure due to non-infectious etiology
- Major congenital anomalies that adversely affect survival, eg CNS malformations
- Metabolic diseases that would affect transplant survival, eg urea cycle disorders
- HIV infection
Since the only chance of survival for patients with SCID is successful transplantation, all patients with SCID will be considered to be potential subjects for the study, regardless of end-organ dysfunction.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Otro: unrelated BM with T cell depletion
Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
|
Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
Otros nombres:
|
Otro: unrelated cord blood
Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g.
not mismatched for both HLA A alleles).
|
Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
Otros nombres:
|
Otro: haplo BM with T cell depletion
If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
|
haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
Otros nombres:
|
Otro: unrelated PBSC with T cell depletion
The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
|
peripheral blood stem cell will be processed for CD34+ cell isolation.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Engraftment
Periodo de tiempo: 100 day
|
Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.
|
100 day
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Donor-derived CD3+ T Lymphocytes >/= 100/mm3
Periodo de tiempo: 1 year
|
Absolute number of donor-derived CD3+ T lymphocytes >/= 100/mm3 in participating subjects.
|
1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe
Periodo de tiempo: 100 days
|
Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia
|
100 days
|
Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV
Periodo de tiempo: 1 year
|
GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.
|
1 year
|
Overall Survival
Periodo de tiempo: 1 year
|
Overalls survival of patient at 1 year post transplant
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Neena Kapoor, M.D., Children's Hospital Los Angeles, University of Southern California
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades metabólicas
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infantil, Recién Nacido, Enfermedades
- Enfermedades Genéticas Congénitas
- Trastornos por deficiencia en la reparación del ADN
- Enfermedades de inmunodeficiencia primaria
- Inmunodeficiencia Combinada Severa
Otros números de identificación del estudio
- CCI-06-00243
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Inmunodeficiencia Combinada Severa
-
Acibadem UniversityTerminadoPaso | Enfermedad de Sever | Apofisitis del calcáneoPavo
-
University of Colorado, DenverTerminadoEnfermedad de SeverEstados Unidos
-
Fundacion PodoactivaTerminadoEnfermedad de Sever | Apofisitis del calcáneoEspaña
-
University of DelawareReclutamientoEnfermedad de Sever | Tendinopatía de Aquiles | Tendinopatía insercional de Aquiles | Apofisitis; calcáneoEstados Unidos
-
Ann & Robert H Lurie Children's Hospital of ChicagoAmerican Medical Society for Sports MedicineDesconocidoSíndrome de Osgood-Schlatter | Síndrome de Sinding-Larsen y Johansson | Enfermedad de Sever | ApofisitisEstados Unidos